Effects of Teriparatide Treatment on Bone Mineral Density in Patients With Osteoporosis: A Short-Term Dose-Response Study

Introduction: Osteoporosis is a chronic bone disease that develops with a decrease in bone mineral density (BMD) along with bone mass. An essential measure in the prevention of osteoporosis is the achievement of normal peak bone mass. Teriparatide (TPTD) functions as an osteoanabolic agent, exerting a dual influence on bone remodeling by modulating both osteogenesis and osteoclastogenesis. Bone mass is determined by dual-energy x-ray absorptiometry (DEXA) quantitative CT scan and has outstanding precision (within 1% to 2%) and has the ability to show the effectiveness of drug intervention.Objective: To assess the effectiveness of TPTD treatment on BMD in osteoporosis patients.Materials and methods: The study is a retrospective, observational, multi-center study of 378 osteoporosis patients who were treated with 20 mu g of subcutaneous TPTD every day for six months. DEXA scores of the hip joints of patients were measured both before and after TPTD treatment.Results: The DEXA scores of the total population pre and post-treatment were-2.75+0.58 and-2.15+0.95 respectively, with a p-value of <0.001, which is statistically significant. In women the pre and posttreatment scores were-2.728+0.52 and-2.276+0.49, with a significant p-value of <0.001 whereas in males, the scores were-2.756+0.72 and-2.108+1.29 respectively, with a significant p-value of <0.05.Conclusion: The six-month treatment with TPTD significantly improved DEXA scores in osteoporosis patients. DEXA score's precision and sensitivity in quantifying impact contribute to effective osteoporosis management, guiding treatment strategies for better outcomes in the Indian population. Further research is warranted to see the long-term effect of TPTD.

Automated summary

The study retrospectively observed 378 osteoporosis patients who were treated with a subcutaneous TPTD dosage of 20μg every day for six months. The DEXA scores of hip joints before and after the treatment were measured. Results showed that the six-month treatment with TPTD significantly improved DEXA scores in osteoporosis patients. Dexa scores precision and sensitivity contribute to effective osteoporosis management.